Schizophrenic Disorders Clinical Trial
Official title:
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
This study evaluates the effect of a cognitive remediation program on neurocognitive, social cognitive and metacognitive functions designed for patients living with a schizophrenia spectrum disorder.
Evaluation of the specific therapeutic efficacy of the ecological cognitive remediation program for schizophrenia spectrum disorder [ECo-Sz] on neurocognitive deficits, social cognition deficits and metacognition deficits of patients with a schizophrenia spectrum disorder. In this double-blind (patients, outcomes assessors) controlled randomized trial the investigators compare patients receiving Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz] to patients benefiting from recovery-oriented therapy [ThOR]. Patients are treated for two months and monitored for four months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00660595 -
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
|
Phase 3 | |
Completed |
NCT02655172 -
Have a Good Grasp of the Worldthe World
|
N/A | |
Completed |
NCT01606436 -
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
|
Phase 1 | |
Completed |
NCT01729650 -
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
|
N/A | |
Completed |
NCT02525315 -
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations
|
Phase 2 | |
Completed |
NCT00488319 -
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
|
Phase 3 | |
Completed |
NCT00088491 -
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
|
Phase 3 | |
Completed |
NCT01279213 -
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
|
Phase 4 | |
Completed |
NCT00600756 -
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
|
Phase 3 | |
Completed |
NCT00572247 -
The Psychiatric Rehabilitation Approach to Weight Loss
|
N/A | |
Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
Completed |
NCT00485823 -
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
|
Phase 4 | |
Active, not recruiting |
NCT00161408 -
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
|
N/A | |
Terminated |
NCT05164289 -
Interest of EMDR Schizophrenic Disorders
|
||
Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
Completed |
NCT00088465 -
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
Withdrawn |
NCT02654405 -
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT02544516 -
Upside Down, Give me the Handle
|
N/A | |
Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 |